Skip to main content

Table 1 Demographic information of participants at baseline (N = 283)

From: Evaluation of PDQ-8 and its relationship with PDQ-39 in China: a three-year longitudinal study

  Median Quartile/Percentage Floor/Ceiling %
Gender (male) 166 58.7%  
Age (year) 57 45–64  
Age of onset (year) 51 41–60  
Duration of disease (month) 36 18–67  
Education (year)
  < 7 29 10.2%  
 7–12 145 51.1%  
  > 12 109 38.5%  
H&Y stage
 1 71 25.1%  
 2 130 45.9%  
 3 73 25.7%  
 4 7 2.5%  
 5 2 0.7%  
UPDRS-III 30 20–38  
LEDD (mg) 300 75–451  
BDI 11 6.0–18.0  
MMSE 28 27–29  
PDQ-8-SI 18.8 9.4–31.3 6.0%/0
PDQ-39-SI 17.3 9.0–27.6 0.4%/0
 Mobility 15 5.0–30.0 14.5%/0
 Activity of daily living 12.5 0.0–28.2 25.8%/0
 Emotional well-being 16.7 8.3–33.3 15.5%/0.4%
 Stigma 18.8 0.0–37.5 25.1%/2.5%
 Social support 0 0.0–8.3 63.6%/0.4%
 Cognitions 18.8 12.5–36.0 11.7%/0.4%
 Communication 8.3 0.0–25.0 45.9%/0.4%
 Bodily discomfort 25 8.3–41.7 18.7%/0.7%
  1. Abbreviations: BDI Beck Depression Inventory, H&Y stage Hoehn and Yahr stage, LEDD Levodopa equivalent daily dose, MMSE Mini–Mental Status Examination, PDQ-8 8-item Parkinson’s disease Questionnaire, PDQ-8-SI PDQ-8 summary index, PDQ-39 39-item Parkinson’s disease Questionnaire, PDQ-39-SI PDQ-39 summary index, UPDRS-III Unified Parkinson’s Disease Rating Scale part III